A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Кой може да участва
Inclusion Criteria:
* Men or women greater than or equal to 18 years old.
* ECOG ≤ 1
* Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through central testing or have documentation of KRAS p.G12C mutation through Amgen Study 20190294 prior to enrollment
Exclusion Criteria:
* Active brain metastases
* Myocardial infarction within 6 months of study day 1
* Gastrointestinal (GI) tract disease causing the inability to take oral medication
Места на провеждане
20
Австралия (1)
Blacktown Hospital
Blacktown , New South Wales
Белгия (1)
Institute Jules Bordet
Brussels
Бразилия (1)
Hospital de Caridade de Ijui
Ijuí , Rio Grande do Sul
Канада (1)
Tom Baker Cancer Centre
Calgary , Alberta
Дания (1)
Herlev og Gentofte Hospital
Herlev
Финландия (1)
Docrates Syopasairaala
Helsinki
Франция (1)
Centre Hospitalier Regional Universitaire - Hopital Morvan
Brest
Гърция (1)
Agios Savvas Anticancer Hospital
Athens
Унгария (1)
Semmelweis Egyetem
Budapest
Италия (1)
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati
Avellino
Япония (1)
Aichi Cancer Center Hospital
Nagoya , Aichi-ken
Нидерландия (1)
Nederlands Kanker Instituut Antoni van Leeuwenhoekziekenhuis
Amsterdam
Полша (1)
Uniwersyteckie Centrum Kliniczne
Gdansk
Russia (1)
Clinical hospital 2, Group of companies medsi
Moscow
Южна Корея (1)
Chungbuk National University Hospital
Cheongju-si, Chungcheongbuk-do
Испания (1)
Hospital Regional Universitario de Malaga
Málaga , AndalucÃ-a
Швеция (1)
Gavle Sjukhus
Gävle
Taiwan (1)
China Medical University Hospital
Taichung
Великобритания (1)
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
БГ
EN